A 24-Year-Old Man With Hemoptysis Found to Have a Chest Mass and Contralateral Axillary Lymphadenopathy

      Case Presentation

      A 24-year-old man, never smoker, with no medical or surgical history, not currently on medications, presented to the ED with a second episode of gross hemoptysis, 4 months after an initial episode that had not previously been evaluated. He described the current episode of hemoptysis as “enough to fill the sink”; however, he did not further quantify. He has no history of recurrent epistaxis, hematemesis, or other evidence of clotting disorder. He denied any fevers, chills, night sweats, or recent travel. He denied any sick contacts and has no history of TB exposure or risk factors. The patient denied any shortness of breath, wheezing, or chest pain. He had no lower extremity pain or swelling. He routinely exercises and generally lives a healthy lifestyle. He is a health care worker who has not routinely worked with patients infected with SARS-CoV-2, although he received his second (of two) COVID-19 vaccines 4 days before presentation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Suggested Reading

        • de Andrade J.M.
        • Marana H.R.
        • Sarmento Filho J.M.
        • Murta E.F.
        • Velludo M.A.
        • Bighetti S.
        Differential diagnosis of axillary masses.
        Tumori. 1996; 82: 596-599
        • Gustafsson B.I.
        • Kidd M.
        • Chan A.
        • Malfertheiner M.V.
        • Modlin I.M.
        Bronchopulmonary neuroendocrine tumors.
        Cancer. 2008; 113: 5-21
        • Studdiford J.
        • Lamb K.
        • Horvath K.
        • Altshuler M.
        • Stonehouse A.
        Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination.
        Pharmacotherapy. 2008; 28: 1194-1197
        • Burger I.A.
        • Husmann L.
        • Hany T.F.
        • Schmid D.T.
        • Schaefer N.G.
        Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine.
        Clin Nucl Med. 2011; 36: 848-853
        • Dialani V.
        • James D.F.
        • Slanetz P.J.
        A practical approach to imaging the axilla.
        Insights Imaging. 2015; 6: 217-229
        • Gaddey H.L.
        • Riegel A.M.
        Unexplained lymphadenopathy: evaluation and differential diagnosis.
        Am Fam Physician. 2016; 94: 896-903
      1. Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention.
        • Edmonds C.E.
        • Zuckerman S.P.
        • Conant E.F.
        Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) vaccination [Published online ahead of print February 5, 2021].
        AJR Am J Roentgenol. 2021;
        • Mehta N.
        • Sales R.M.
        • Babagbemi K.
        • et al.
        Unilateral axillary adenopathy in the setting of COVID-19 vaccine.
        Clin Imaging. 2021; 75: 12-15